Concepts (261)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 49 | 2024 | 866 | 7.700 |
Why?
|
| Heart Failure | 45 | 2024 | 1346 | 5.580 |
Why?
|
| Heart Transplantation | 24 | 2025 | 774 | 3.030 |
Why?
|
| Stroke | 16 | 2022 | 1038 | 1.630 |
Why?
|
| Prosthesis Implantation | 3 | 2024 | 129 | 1.330 |
Why?
|
| Thrombosis | 10 | 2018 | 312 | 1.140 |
Why?
|
| Registries | 7 | 2025 | 904 | 1.130 |
Why?
|
| Thoracic Surgery | 3 | 2024 | 50 | 1.060 |
Why?
|
| Thoracotomy | 2 | 2024 | 64 | 0.990 |
Why?
|
| Sternotomy | 1 | 2024 | 24 | 0.860 |
Why?
|
| Organ Preservation | 7 | 2025 | 131 | 0.810 |
Why?
|
| Retrospective Studies | 32 | 2024 | 9679 | 0.780 |
Why?
|
| Tissue Donors | 10 | 2025 | 531 | 0.770 |
Why?
|
| Treatment Outcome | 29 | 2025 | 8727 | 0.750 |
Why?
|
| Patient Isolation | 1 | 2020 | 14 | 0.680 |
Why?
|
| Heart | 2 | 2023 | 584 | 0.670 |
Why?
|
| Humans | 79 | 2025 | 92303 | 0.640 |
Why?
|
| Prosthesis Design | 9 | 2024 | 302 | 0.640 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2019 | 10 | 0.640 |
Why?
|
| Heart Aneurysm | 1 | 2019 | 22 | 0.630 |
Why?
|
| Surgeons | 1 | 2023 | 263 | 0.620 |
Why?
|
| Middle Aged | 44 | 2025 | 27043 | 0.600 |
Why?
|
| Equipment Failure | 3 | 2018 | 123 | 0.600 |
Why?
|
| Betacoronavirus | 1 | 2020 | 270 | 0.530 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2018 | 151 | 0.510 |
Why?
|
| Mortality | 1 | 2017 | 150 | 0.510 |
Why?
|
| Male | 46 | 2025 | 43924 | 0.480 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2018 | 71 | 0.480 |
Why?
|
| Lung Transplantation | 5 | 2024 | 350 | 0.470 |
Why?
|
| Tissue and Organ Procurement | 3 | 2024 | 380 | 0.470 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 329 | 0.470 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 315 | 0.460 |
Why?
|
| Hospitals | 1 | 2017 | 313 | 0.460 |
Why?
|
| Perfusion | 3 | 2025 | 261 | 0.460 |
Why?
|
| Electric Power Supplies | 1 | 2014 | 8 | 0.440 |
Why?
|
| Pandemics | 1 | 2020 | 808 | 0.440 |
Why?
|
| Aged | 26 | 2024 | 19952 | 0.430 |
Why?
|
| Female | 42 | 2025 | 47894 | 0.400 |
Why?
|
| Postoperative Complications | 6 | 2022 | 2450 | 0.380 |
Why?
|
| Ventricular Function, Left | 4 | 2024 | 638 | 0.370 |
Why?
|
| Waiting Lists | 4 | 2023 | 200 | 0.370 |
Why?
|
| Societies, Medical | 3 | 2024 | 596 | 0.360 |
Why?
|
| Survival Rate | 9 | 2024 | 1927 | 0.360 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2022 | 865 | 0.360 |
Why?
|
| Agricultural Workers' Diseases | 1 | 2011 | 18 | 0.350 |
Why?
|
| Commerce | 1 | 2011 | 31 | 0.350 |
Why?
|
| Time Factors | 11 | 2024 | 5430 | 0.350 |
Why?
|
| Agriculture | 1 | 2011 | 41 | 0.350 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2020 | 205 | 0.340 |
Why?
|
| Hemodynamics | 5 | 2023 | 757 | 0.330 |
Why?
|
| Adult | 24 | 2025 | 27535 | 0.330 |
Why?
|
| Proportional Hazards Models | 6 | 2018 | 871 | 0.300 |
Why?
|
| Follow-Up Studies | 10 | 2022 | 3773 | 0.300 |
Why?
|
| Leukemia | 1 | 2011 | 324 | 0.300 |
Why?
|
| Brain Death | 3 | 2025 | 86 | 0.300 |
Why?
|
| Prospective Studies | 9 | 2024 | 4469 | 0.290 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2022 | 206 | 0.290 |
Why?
|
| United States | 8 | 2024 | 7346 | 0.280 |
Why?
|
| Risk Factors | 11 | 2019 | 5705 | 0.270 |
Why?
|
| Vascular Diseases | 1 | 2007 | 120 | 0.250 |
Why?
|
| Sternum | 1 | 2006 | 35 | 0.250 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2023 | 190 | 0.240 |
Why?
|
| Thorax | 2 | 2023 | 75 | 0.240 |
Why?
|
| Shock, Cardiogenic | 2 | 2017 | 133 | 0.240 |
Why?
|
| Equipment Design | 3 | 2022 | 420 | 0.240 |
Why?
|
| Heart Ventricles | 3 | 2023 | 795 | 0.230 |
Why?
|
| Odds Ratio | 3 | 2017 | 694 | 0.230 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2023 | 15 | 0.210 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 1920 | 0.210 |
Why?
|
| Atrioventricular Block | 1 | 2023 | 27 | 0.210 |
Why?
|
| Cohort Studies | 5 | 2022 | 2976 | 0.200 |
Why?
|
| Hospitalization | 4 | 2023 | 926 | 0.190 |
Why?
|
| Mitral Valve | 2 | 2020 | 275 | 0.190 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2023 | 143 | 0.190 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2023 | 123 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 490 | 0.180 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2022 | 56 | 0.180 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 98 | 0.180 |
Why?
|
| Enoxaparin | 1 | 2020 | 24 | 0.170 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 31 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 996 | 0.170 |
Why?
|
| Heparin | 1 | 2020 | 185 | 0.160 |
Why?
|
| Photopheresis | 1 | 1999 | 12 | 0.160 |
Why?
|
| Prognosis | 4 | 2022 | 3872 | 0.160 |
Why?
|
| Graft Survival | 4 | 2024 | 935 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2023 | 955 | 0.160 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 95 | 0.150 |
Why?
|
| Postoperative Hemorrhage | 1 | 2018 | 46 | 0.150 |
Why?
|
| Lung Diseases, Fungal | 1 | 1998 | 18 | 0.150 |
Why?
|
| Heart Valve Prosthesis | 2 | 2014 | 99 | 0.140 |
Why?
|
| Anticoagulants | 2 | 2020 | 444 | 0.140 |
Why?
|
| Aspergillosis | 1 | 1998 | 39 | 0.140 |
Why?
|
| Hemolysis | 2 | 2017 | 62 | 0.140 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 130 | 0.140 |
Why?
|
| Hepatitis C | 1 | 2019 | 179 | 0.140 |
Why?
|
| Graft Rejection | 2 | 2004 | 1110 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 1998 | 145 | 0.140 |
Why?
|
| Magnets | 1 | 2017 | 12 | 0.140 |
Why?
|
| Brain Ischemia | 2 | 2019 | 405 | 0.130 |
Why?
|
| Prosthesis Failure | 4 | 2024 | 118 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1998 | 268 | 0.130 |
Why?
|
| Algorithms | 3 | 2018 | 1960 | 0.130 |
Why?
|
| Reoperation | 4 | 2019 | 652 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 1998 | 339 | 0.120 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 1180 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 452 | 0.110 |
Why?
|
| Cause of Death | 1 | 2015 | 270 | 0.110 |
Why?
|
| Age Factors | 4 | 2024 | 1902 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6916 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 436 | 0.110 |
Why?
|
| Intention to Treat Analysis | 3 | 2019 | 75 | 0.110 |
Why?
|
| Coronary Vessels | 3 | 2008 | 197 | 0.110 |
Why?
|
| Death | 2 | 2024 | 92 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 118 | 0.100 |
Why?
|
| Lung | 4 | 2024 | 1337 | 0.100 |
Why?
|
| Italy | 1 | 2011 | 109 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2011 | 173 | 0.090 |
Why?
|
| Extracorporeal Circulation | 2 | 2022 | 36 | 0.080 |
Why?
|
| Incidence | 2 | 2014 | 1661 | 0.080 |
Why?
|
| Patient Selection | 3 | 2016 | 688 | 0.080 |
Why?
|
| Life Style | 1 | 2011 | 176 | 0.080 |
Why?
|
| Sex Factors | 3 | 2018 | 1095 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1764 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 492 | 0.080 |
Why?
|
| Materials Testing | 2 | 2018 | 94 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2021 | 444 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2007 | 59 | 0.070 |
Why?
|
| Postoperative Care | 2 | 2006 | 238 | 0.070 |
Why?
|
| Adolescent | 4 | 2021 | 9491 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 1999 | 1733 | 0.060 |
Why?
|
| Myocarditis | 1 | 2006 | 56 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2005 | 76 | 0.060 |
Why?
|
| Aortic Aneurysm | 1 | 2005 | 79 | 0.060 |
Why?
|
| Annual Reports as Topic | 1 | 2024 | 3 | 0.060 |
Why?
|
| Aorta, Thoracic | 1 | 2006 | 167 | 0.060 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2006 | 114 | 0.060 |
Why?
|
| Aorta | 1 | 2005 | 291 | 0.050 |
Why?
|
| Echocardiography, Doppler | 1 | 2005 | 193 | 0.050 |
Why?
|
| Coronary Artery Bypass | 2 | 2023 | 245 | 0.050 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2004 | 192 | 0.050 |
Why?
|
| Wound Healing | 1 | 2006 | 371 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2005 | 260 | 0.050 |
Why?
|
| Pneumonectomy | 2 | 1998 | 214 | 0.050 |
Why?
|
| Quality of Life | 2 | 2024 | 1744 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 226 | 0.050 |
Why?
|
| Tricuspid Valve | 1 | 2023 | 107 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2006 | 283 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2022 | 159 | 0.050 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2004 | 244 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 380 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 172 | 0.050 |
Why?
|
| Body Size | 1 | 2022 | 95 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 86 | 0.050 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2022 | 83 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 165 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 743 | 0.050 |
Why?
|
| Young Adult | 3 | 2018 | 6628 | 0.040 |
Why?
|
| Kansas | 1 | 2020 | 7 | 0.040 |
Why?
|
| Indiana | 1 | 2020 | 13 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2020 | 37 | 0.040 |
Why?
|
| Patient Safety | 1 | 2023 | 220 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2023 | 339 | 0.040 |
Why?
|
| CD59 Antigens | 1 | 2000 | 17 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 311 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2020 | 65 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 2369 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 868 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 1999 | 127 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2000 | 370 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2019 | 134 | 0.040 |
Why?
|
| Child | 2 | 2021 | 7303 | 0.040 |
Why?
|
| Recurrence | 2 | 1998 | 1180 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 154 | 0.040 |
Why?
|
| Walk Test | 1 | 2018 | 26 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 159 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 1998 | 225 | 0.040 |
Why?
|
| Neutropenia | 1 | 1998 | 217 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 1998 | 475 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1998 | 125 | 0.030 |
Why?
|
| Tachycardia, Ventricular | 1 | 1998 | 125 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1998 | 289 | 0.030 |
Why?
|
| Heart Septum | 1 | 1997 | 47 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 1998 | 355 | 0.030 |
Why?
|
| Neutrophils | 1 | 1998 | 323 | 0.030 |
Why?
|
| Heart Arrest, Induced | 1 | 1996 | 30 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 1999 | 231 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2017 | 256 | 0.030 |
Why?
|
| Swine | 3 | 2004 | 607 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2019 | 498 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 157 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2020 | 393 | 0.030 |
Why?
|
| Device Removal | 1 | 2017 | 163 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 1998 | 1015 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 969 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1997 | 439 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 661 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 989 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2018 | 909 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1997 | 335 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 1997 | 547 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1997 | 402 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 2014 | 152 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 1997 | 2394 | 0.020 |
Why?
|
| Immunoglobulin M | 2 | 2004 | 161 | 0.020 |
Why?
|
| Child, Preschool | 1 | 1998 | 3803 | 0.020 |
Why?
|
| Preoperative Care | 2 | 2006 | 405 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1150 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2683 | 0.020 |
Why?
|
| Washington | 1 | 2008 | 50 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 2556 | 0.020 |
Why?
|
| Giant Cells | 1 | 2006 | 19 | 0.020 |
Why?
|
| Rupture | 1 | 2006 | 60 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2005 | 205 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 54 | 0.010 |
Why?
|
| Tyrosine | 1 | 2005 | 133 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2005 | 241 | 0.010 |
Why?
|
| Indoles | 1 | 2005 | 306 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 807 | 0.010 |
Why?
|
| Animals | 4 | 2005 | 28045 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 856 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 651 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2004 | 380 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2004 | 468 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1938 | 0.010 |
Why?
|
| Heart Valves | 1 | 2000 | 25 | 0.010 |
Why?
|
| Complement Hemolytic Activity Assay | 1 | 2000 | 1 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2004 | 855 | 0.010 |
Why?
|
| Lung Compliance | 1 | 2000 | 15 | 0.010 |
Why?
|
| Complement C3a | 1 | 2000 | 11 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2000 | 104 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 2000 | 92 | 0.010 |
Why?
|
| Safety | 1 | 2000 | 145 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2000 | 324 | 0.010 |
Why?
|
| Models, Animal | 1 | 2000 | 281 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 4066 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1992 | 3054 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2000 | 997 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2000 | 291 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2448 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2000 | 460 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1998 | 391 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1997 | 50 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 1997 | 44 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1997 | 88 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 1998 | 165 | 0.010 |
Why?
|
| fas Receptor | 1 | 1997 | 78 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1997 | 299 | 0.010 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1996 | 72 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1997 | 269 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 1052 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1016 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 923 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1997 | 358 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1998 | 1756 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1997 | 2037 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1992 | 485 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1992 | 324 | 0.010 |
Why?
|
| Mastectomy | 1 | 1992 | 257 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 1992 | 400 | 0.010 |
Why?
|
| Chicago | 1 | 1992 | 1466 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 1992 | 2035 | 0.000 |
Why?
|